Fig. 5: Effects of gilteritinib treatment on the global gene expression profile.
From: Antitumor activity of gilteritinib, an inhibitor of AXL, in human solid tumors
Gene expression studies were conducted by RNA-seq in KYSE30, A2780, and HGC-27 cells treated with vehicle control or 1 μM gilteritinib for 24 h. Each group represents triplicate samples. The expression of DEGs in KYSE30 (A), A2780 (B), and HGC-27 (C) cells between the vehicle and gilteritinib treatment. Upregulated and downregulated genes are shown in red and green, respectively. Values are presented as the log10 of tag counts. Number of overlapping DEGs in KYSE30 (D), A2780 (E), and HGC-27 (F) treated cells as compared to the vehicle-treated cells. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of DEGs in the gilteritinib treated samples as compared to the vehicle-treated samples in KYSE30 (G), A2780 (H), and HGC-27 (I) cells. J Analysis of the PI3K/AKT pathway, AMPK pathway, p53 pathway, cell cycle-related proteins, and antiapoptotic proteins, with GAPDH or β-tubulin used as the loading control.
